Clazakizumab in Chronic Active Antibody-Mediated Kidney Transplant Rejection: Results of the IMAGINE Phase 3 Study

被引：0
|
作者：
Djamali, Arjang [1 ]
Bohmig, Georg [4 ]
Chadban, Steven J. [5 ]
Kumar, Deepali [6 ]
Mannon, Roslyn B. [7 ]
van Gelder, Teun [8 ]
Schultz-Hauser, Gabriele [9 ]
Alperovich Lehrer, Gabriela [10 ]
Preiss, Ralph [11 ]
Raychaudhuri, Aparna [2 ]
Lee, Laurie [2 ]
Nickerson, Peter W. [3 ]
机构：
[1] Maine Med Ctr, Portland, ME USA
[2] CSL Behring LLC, King Of Prussia, PA USA
[3] Univ Manitoba, Winnipeg, MB, Canada
[4] Med Univ Vienna, Vienna, Austria
[5] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[6] Univ Toronto, Toronto, ON, Canada
[7] Univ Nebraska Med Ctr, Omaha, NE USA
[8] Leiden Univ Med Ctr, Leiden, Netherlands
[9] CSL Behring, Marburg, Germany
[10] CSL Vifor, Madrid, Spain
[11] CSL Behring, Bern, Switzerland
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2024年 / 35卷 / 10期
关键词：
D O I：
10.1681/ASN.2024ktr5vxvn
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
SA-OR84
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: Phase 3 IMAGINE Study Design
    Nickerson, P.
    Boehmig, G.
    Chadban, S.
    Kumar, D.
    Mannon, R. B.
    Van Gelder, T.
    Adler, S.
    Chong, E.
    Djamali, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 737 - 737
  • [2] Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design
    Nickerson, Peter W.
    Boehmig, Georg A.
    Chadban, Steve
    Kumar, Deepali
    Mannon, Roslyn B.
    van Gelder, Teun
    Lee, James C.
    Adler, Scott
    Chong, Edward
    Djamali, Arjang
    TRIALS, 2022, 23 (01)
  • [3] Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design
    Peter W. Nickerson
    Georg A. Böhmig
    Steve Chadban
    Deepali Kumar
    Roslyn B. Mannon
    Teun van Gelder
    James C. Lee
    Scott Adler
    Edward Chong
    Arjang Djamali
    Trials, 23
  • [4] Rationale for the IMAGINE study for chronic active antibody-mediated rejection (caAMR) in kidney transplantation
    Nickerson, Peter W. W.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 38 - 44
  • [5] Mesangiolysis in Chronic Active Antibody-mediated Rejection in Kidney Transplant Biopsies
    Suto, Yuki
    Oguchi, Hideyo
    Tochigi, Naobumi
    Mikami, Tetuo
    Shinoda, Kazunobu
    Honda, Kazuho
    Kounoue, Noriyuki
    Hashimoto, Junya
    Muramatsu, Masaki
    Itabashi, Yoshihiro
    Sakai, Ken
    NEPHRON, 2023, : 14 - 21
  • [6] Treatment of Chronic Active Antibody-Mediated Kidney Transplant Rejection With Intravenous Immunoglobulin
    Rapetskaya, Nadzeya
    Komissarov, Kirill
    Kalachyk, Aleh
    TRANSPLANTATION, 2022, 106 (09) : S572 - S572
  • [7] Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients
    Boonpheng, Boonphiphop
    De Castro, Iris Camille C.
    Ng, Yue-Harn
    Blosser, Christopher
    Bakthavatsalam, Ramasamy
    Gimferrer, Idoia
    Smith, Kelly
    Leca, Nicolae
    CLINICAL TRANSPLANTATION, 2023, 37 (05)
  • [8] Impact of ABO incompatibility and early antibody-mediated rejection on chronic antibody-mediated rejection in kidney transplant patients
    Heo, Ga Young
    Jang, Yunyoung
    Choi, Hyungwook
    Kim, Yong Chul
    Han, Seung Seok
    Kim, Hyung Woo
    Lee, Juhan
    Huh, Kyu Ha
    Kim, Beom Seok
    Yang, Jaeseok
    JOURNAL OF NEPHROLOGY, 2023, 36 (09) : 2571 - 2580
  • [9] Impact of ABO incompatibility and early antibody-mediated rejection on chronic antibody-mediated rejection in kidney transplant patients
    Ga Young Heo
    Yunyoung Jang
    Hyungwook Choi
    Yong Chul Kim
    Seung Seok Han
    Hyung Woo Kim
    Juhan Lee
    Kyu Ha Huh
    Beom Seok Kim
    Jaeseok Yang
    Journal of Nephrology, 2023, 36 : 2571 - 2580
  • [10] A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection
    Doberer, Konstantin
    Duerr, Michael
    Halloran, Philip F.
    Eskandary, Farsad
    Budde, Klemens
    Regele, Heinz
    Reeve, Jeff
    Borski, Anita
    Kozakowski, Nicolas
    Reindl-Schwaighofer, Roman
    Waiser, Johannes
    Lachmann, Nils
    Schranz, Sabine
    Firbas, Christa
    Muehlbacher, Jakob
    Gelbenegger, Georg
    Perkmann, Thomas
    Wahrmann, Markus
    Kainz, Alexander
    Ristl, Robin
    Halleck, Fabian
    Bond, Gregor
    Chong, Edward
    Jilma, Bernd
    Boehmig, Georg A.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (03): : 708 - 722
12345